Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
COYA
Strong SellSinkerCoya Therapeutics, Inc. · Healthcare · United States · $108M · Avg Vol: $523K/d
COMPANY DESCRIPTION
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel regulatory T cell (Treg) enhancing therapies for neurodegenerative and autoimmune diseases. Its competitive edge lies in targeting the immune system's role in these complex conditions with innovative Treg-based approaches, aiming to restore immune balance. As a clinical-stage firm, its valuation is heavily tied to successful clinical trial outcomes and regulatory approvals.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 6.0M | 3.6M | 7.9M | 15.1% | 8.0M | 1.0M | 5.0M | -21.0% |
| EPS | -1.95 | -0.79 | -0.98 | -1.27 | — | -1.07 | -1.37 | -1.88 | — |
| Shares | 23.5M | 14.4M | 16.7M | 20.9M | -10.8% | 23.5M | — | — | — |
| Debt | 13.0M | — | — | — | — | — | — | — | — |
| Equity | -8.4M | 35.6M | 39.6M | 43.0M | 9.9% | — | — | — | — |
| Op CF | -7.2M | -11.2M | -10.3M | -10.7M | — | -15.7M | — | — | — |
| Inv CF | -0.5M | -0.5M | -25.0K | -1.2M | — | — | — | — | — |
| Fin CF | 9.4M | 38.4M | 16.0M | 20.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of COYA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| COYA | Coya Therapeutics, Inc.(you) | $108M | 10 | Strong Sell |
| VRCA | Verrica Pharmaceuticals Inc. | $98M | 8 | Strong Sell |
| GUTS | Fractyl Health, Inc. | $105M | 14 | Strong Sell |
| DWTX | Dogwood Therapeutics, Inc. | $90M | 9 | Strong Sell |
| RANI | Rani Therapeutics Holdings, Inc. | $118M | 7 | Strong Sell |
| ONCY | Oncolytics Biotech Inc. | $109M | 6 | Strong Sell |
| CGTX | Cognition Therapeutics, Inc. | $97M | 13 | Strong Sell |
| KLRS | Kalaris Therapeutics, Inc. | $96M | 7 | Strong Sell |
| CNTB | Connect Biopharma Holdings Limited | $140M | 10 | Strong Sell |
| ANIX | Anixa Biosciences, Inc. | $118M | 14 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%